Teclistamab in Relapsed or Refractory Multiple Myeloma. Reply.
Journal Articles
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
status
publication date
- November 3, 2022
has subject area
- 11 Medical and Health Sciences (FoR)
- Antibodies, Bispecific (MeSH)
- Antineoplastic Agents (MeSH)
- Antineoplastic Combined Chemotherapy Protocols (MeSH)
- General & Internal Medicine (Science Metrix)
- Humans (MeSH)
- Multiple Myeloma (MeSH)
- Neoplasm Recurrence, Local (MeSH)
published in
- New England Journal of Medicine Journal